|Bid||122.24 x 800|
|Ask||122.23 x 1100|
|Day's Range||121.66 - 122.66|
|52 Week Range||118.62 - 148.32|
|PE Ratio (TTM)||270.55|
|Forward Dividend & Yield||3.60 (2.94%)|
|1y Target Est||N/A|
Allergan (AGN), a leading specialty pharmaceutical company, is focused on developing, manufacturing, and commercializing pharmaceutical and biologic products.
Meanwhile, the nation’s largest banks are preparing for a timeout from the courtroom following years of being pummeled by shareholder and investor lawsuits in the wake of the Great Recession.
Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches. The company provided an update regarding its Enforce Phase III clinical development program for the treatment of cluster headaches on June 15.
is another company that Jim Cramer put in his new GLOOM index last night on his Mad Money show on CNBC. In this updated daily bar chart of JNJ, below, we have more bearish signals than bullish ones. JNJ broke down below the rising 50-day moving average line in late January and the slope of the line quickly turned negative.
Purdue Pharma LP, Johnson & Johnson and other opioid makers faced one of the first extensive review of their legal defenses to state claims that they violated consumer-protection laws and created a public nuisance with the sale of the pain killers. New York state court Judge Jerry Garguilo on Monday rejected the pharma companies’ requests for the lawsuits be thrown out on a myriad of grounds, concluding lawyers for eight counties could move forward with their claims. While the ruling is based solely on New York law, it could provide a roadmap for other judges around the U.S. weighing whether states and local governments can proceed with claims that Purdue and other opioid makers understated the risks of prescription opioids and overstated their benefits.
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA.
Congratulations! You've just retired. Investors and financial planners both suggest that dividend stocks can be a great source of income for those looking to supplement their retirement savings. The blue-chip stock's staying power and brand recognition should be viewed favorably by retiree investors, says Robert Johnson, principal at the Fed Policy Investment Research Group.
Swiss biotech Idorsia, spun off from Actelion last June with a $1 billion investment from buyer Johnson & Johnson, will seek fresh funding in 2019 to support late-stage trials of drugs getting underway, its CEO told Reuters. French founders Jean-Paul Clozel and his wife, Martine Clozel, sold Actelion for $30 billion last year, but only after extracting rights to 11 prized drugs in development, including an insomnia medicine nicknamed DORA. With 650 employees, Jean-Paul Clozel expects to burn through Idorsia's cash in about two years, before his drug hopefuls generate revenue - typical of the biotech industry where the risk of pipeline failures is ever-present but the rewards of striking paydirt, as was the case with Actelion, can be vast.
The University of North Florida is temporarily housing a highly advanced microscope, the only one of its kind in North America.
Several big pharma companies are about to lose patent exclusivity for blockbuster drugs. Should investors be worried?
Multinational drug companies in China are fighting to hold on to top talent as senior local staff leave to join a booming domestic biotechnology sector drawing record investment. $11.7bn of venture capital investment in 2017, more than double the $5.3bn invested in 2016, according to consultancy ChinaBio, with about $2.6bn going to drug developers. “I see clearly the opportunity for Chinese companies and for indigenous innovation for patients in China,” said Xiaobin Wu, who was Pfizer’s China manager from 2009 until he joined local cancer drug developer BeiGene last month.
Moody's Investors Service ("Moody's) downgraded LifeScan Global Corporation's ("LifeScan") first lien term loan rating to B2 from B1. At the same time Moody's affirmed all other ratings of LifeScan as detailed below including the B2 Corporate Family Rating.
Morningstar’s annual investment conference in Chicago last week was noticeably different than in years past. The 30th iteration focused less on stocks, funds, and other investments, and instead emphasized technology and tools to analyze them. The three-day gathering also served up big-picture thinking from luminaries such as veteran investor and environmental evangelist Jeremy Grantham, and Nobel Prize–winning behavioral psychologist Danny Kahneman.
Dividend reinvestment is an amazingly powerful investment strategy. In fact, studies have shown that over a 20-year holding period, dividends account for 60% of all the gains in the S&P 500! Think about this for a minute. Since 1998, the S&P 500 would be around 60% lower if not for the benefits attributed to dividends.
Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen
In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place. Conversely, the fact that Warren Buffett’s favorite holding period is “forever” and how he’s got a track record most investors would envy is just as telling. With that as the backdrop, here’s a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves.
Jim Cramer proposes starting a new exchange-traded fund with the stocks that scare investors most when trade tensions run high.